Theyab A, Algahtani M, Alsharif KF et al (2021) New insight into the mechanism of granulocyte colony-stimulating factor (G-CSF) that induces the mobilization of neutrophils. Hematology 26(1):628–636

Article  CAS  PubMed  Google Scholar 

Welte K, Platzer E, Lu L et al (1985) Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A 82(5):1526–1530

Article  CAS  PubMed  PubMed Central  Google Scholar 

Souza LM, Boone TC, Gabrilove J et al (1986) Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232(4746):61–65

Article  CAS  PubMed  Google Scholar 

Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199–3212

Article  CAS  PubMed  Google Scholar 

Griffiths EA, Roy V, Alwan L et al (2022) NCCN Guidelines® insights: hematopoietic growth factors, Version 1.2022. J Natl Compr Canc Netw 20(5):436–442

Article  PubMed  Google Scholar 

Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32

Article  CAS  PubMed  Google Scholar 

Green MD, Koelbl H, Baselga J et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14(1):29–35

Article  CAS  PubMed  Google Scholar 

Mouchemore KA, Anderson RL (2021) Immunomodulatory effects of G-CSF in cancer: therapeutic implications. Semin Immunol 54:101512

Article  CAS  PubMed  Google Scholar 

Waight JD, Hu Q, Miller A et al (2011) Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS ONE 6(11):e27690

Article  CAS  PubMed  PubMed Central  Google Scholar 

Voloshin T, Gingis-Velitski S, Bril R et al (2011) G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood 118(12):3426–3435

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kowanetz M, Wu X, Lee J et al (2010) Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A 107(50):21248–21255

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yeo B, Redfern AD, Mouchemore KA et al (2018) The dark side of granulocyte-colony stimulating factor: a supportive therapy with potential to promote tumour progression. Clin Exp Metastasis 35(4):255–267

Article  CAS  PubMed  Google Scholar 

Zhang L, Yao J, Wei Y, et al. Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. Sci Transl Med. 2020;12(545).

Cao Y, Slaney CY, Bidwell BN et al (2014) BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity. Cancer Res 74(18):5091–5102

Article  CAS  PubMed  Google Scholar 

Kawano M, Mabuchi S, Matsumoto Y et al (2015) The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer. Sci Rep 5:18217

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 71(3):209–249

Article  PubMed  Google Scholar 

Horn L, Mansfield AS, Szczęsna A et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220–2229

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212):1929–1939

Article  CAS  PubMed  Google Scholar 

Noda K, Nishiwaki Y, Kawahara M et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346(2):85–91

Article  CAS  PubMed  Google Scholar 

Okamoto H, Watanabe K, Kunikane H et al (2007) Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 97(2):162–169

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishio M, Sugawara S, Atagi S et al (2019) Subgroup analysis of Japanese patients in a phase III study of atezolizumab in extensive-stage small-cell lung cancer (IMpower133). Clin Lung Cancer 20(6):469–76.e1

Article  CAS  PubMed  Google Scholar 

Hotta K, Nishio M, Saito H et al (2021) First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. Int J Clin Oncol 26(6):1073–1082

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48(3):452–458

Article  CAS  PubMed  Google Scholar 

Nicolás-Ávila J, Adrover JM, Hidalgo A (2017) Neutrophils in homeostasis, immunity, and cancer. Immunity 46(1):15–28

Article  PubMed  Google Scholar 

Templeton AJ, McNamara MG, Šeruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124

Article  PubMed  Google Scholar 

Diem S, Schmid S, Krapf M et al (2017) Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 111:176–181

Article  PubMed  Google Scholar 

Pilatova K, Bencsikova B, Demlova R et al (2018) Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment. Cancer Immunol Immunother 67(12):1919–1929

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alshetaiwi H, Pervolarakis N, McIntyre LL, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020;5(44).

Shojaei F, Wu X, Qu X et al (2009) G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A 106(16):6742–6747

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee YS, Saxena V, Bromberg JS et al (2021) G-CSF promotes alloregulatory function of MDSCs through a c-Kit dependent mechanism. Cell Immunol 364:104346

Article  CAS  PubMed  Google Scholar 

Mamesaya N, Kodama H, Iida Y et al (2023) Efficacy and safety of carboplatin and etoposide in older extensive-stage small-cell lung cancer patients with a poor performance status. Thorac Cancer 14(9):805–814

Article  CAS  PubMed